Vanguard Group’s Opiant Pharmaceuticals OPNT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
– Sell
-190,773
Closed -$3.87M – 4615
2022
Q4
$3.87M Buy
190,773
+3,615
+2% +$55.4K ﹤0.01% 3425
2022
Q3
$2.01M Hold
187,158
– – ﹤0.01% 3740
2022
Q2
$2.24M Hold
187,158
– – ﹤0.01% 3759
2022
Q1
$4.01M Buy
187,158
+8,699
+5% +$230K ﹤0.01% 3631
2021
Q4
$6M Buy
178,459
+40,689
+30% +$1.13M ﹤0.01% 3508
2021
Q3
$3.55M Buy
137,770
+805
+0.6% +$14.4K ﹤0.01% 3841
2021
Q2
$1.83M Buy
136,965
+23,935
+21% +$296K ﹤0.01% 3989
2021
Q1
$1.2M Buy
113,030
+14,101
+14% +$161K ﹤0.01% 3976
2020
Q4
$794K Sell
98,929
-3,422
-3% -$26.9K ﹤0.01% 3879
2020
Q3
$766K Sell
102,351
-3,971
-4% -$35.3K ﹤0.01% 3719
2020
Q2
$960K Hold
106,322
– – ﹤0.01% 3624
2020
Q1
$1.02M Hold
106,322
– – ﹤0.01% 3488
2019
Q4
$1.53M Hold
106,322
– – ﹤0.01% 3522
2019
Q3
$1.65M Sell
106,322
-18,251
-15% -$254K ﹤0.01% 3509
2019
Q2
$1.65M Hold
124,573
– – ﹤0.01% 3525
2019
Q1
$1.64M Buy
124,573
+1,573
+1% +$22.9K ﹤0.01% 3510
2018
Q4
$1.78M Buy
123,000
+17,568
+17% +$287K ﹤0.01% 3411
2018
Q3
$1.88M Buy
105,432
+21,151
+25% +$366K ﹤0.01% 3559
2018
Q2
$1.2M Buy
84,281
+3,550
+4% +$62.4K ﹤0.01% 3639
2018
Q1
$1.55M Buy
80,731
+71,170
+744% +$1.54M ﹤0.01% 3541
2017
Q4
$220K Buy
+9,561
New +$306K ﹤0.01% 3917

Vanguard Group's OPNT Position: Q1 2023 in Review

Vanguard Group sold out of Opiant Pharmaceuticals (OPNT) in Q1 2023, closing a stake of 190,773 shares — an estimated $3.87M sold.

Vanguard Group first reported a position in OPNT in Q4 2017 and held it in 21 quarters. The position peaked at $6M in Q4 2021. 0 funds tracked by Wall St. Rank hold OPNT as of Q1 2023.

  • Vanguard Group reported no remaining Opiant Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Vanguard Group sold 190,773 Opiant Pharmaceuticals shares in Q1 2023, an estimated $3.87M.
  • Vanguard Group first reported a position in Opiant Pharmaceuticals in Q4 2017 and held it in 21 quarters.
  • Vanguard Group's Opiant Pharmaceuticals position peaked at $6M in Q4 2021.
  • 0 funds tracked by Wall St. Rank held Opiant Pharmaceuticals as of Q1 2023.

Based on Vanguard Group's 13F filing for Q1 2023, filed 15 May 2023.